Early test results for U.S. drug ‘biggest breakthrough’ for pancreatic cancer, says Canadian oncologist
Summary
- U.S. drugmaker Erasca reported that its experimental pill ERAS-0015 reduced tumors in nearly half of patients with advanced pancreatic & lung cancers during early-stage trials.
- 44% of 25 patients with pancreatic cancer saw substantial tumor shrinkage after taking a 32 mg daily dose of the drug.
- 69% of patients with the two most common genetic variations of pancreatic cancer experienced positive results.
- Tumors diminished in 60% of lung cancer patients (three of five) who had previously received immunotherapy & chemotherapy.
- Erasca plans to begin late-stage clinical trials for ERAS-0015 & another treatment called ERAS-4001 in 2027.
- Dr. Jennifer Knox of Toronto's Princess Margaret Cancer Centre will supervise the Canadian portion of the global trials next year.
- Knox described the drug as a major breakthrough for pancreatic cancer, noting that the mutant RAS protein targeted by the drug is present in approximately 95% of such cases.
- This follows a previous breakthrough by Revolution Medicines using daraxonrasib, which doubled patient survival times & is now licensed in the U.S.
- Over 90 drugs targeting mutant RAS proteins are currently in development after 40 years of study.
- The drug works by blocking mutant RAS proteins that act as "on-off" switches for cell growth, preventing cancer cells from multiplying.
- While the treatment was generally well-tolerated, one patient previously died from lung inflammation while taking a 24 mg dose.
- Experts emphasize that longer trials are necessary to ensure microscopic cancer cells do not return.
An experimental U.S. drug that saw positive results in patients during early tests is a major ‘breakthrough’ for cancer patients, Canadian doctors say.